Neurocrine Bio Drug Licensed From Takeda Flunks Mid-Stage Test in Depression
The Phase 2 failure in major depressive disorder marks the second time in a little…
Neurocrine Bio Drug Licensed From Takeda Flunks Mid-Stage Test in Depression
The Phase 2 failure in major depressive disorder marks the second time in a little more than a year that Neurocrine Biosciences has reported a drug licensed from Takeda Pharmaceutical fell short in the clinic. Last year, a different drug from this partnership failed a mid-stage test in schizophrenia. The post Neurocrine Bio Drug Licensed…
Why Elderly Americans Are Bearing the Brunt of the Government Shutdown’s Impact
Time is of the essence, particularly for those with cognitive conditions. The loss of telehealth flexibilities, combined with disruptions to Medicaid, could have devastating consequences for millions of patients with dementia and other cognitive and behavioral conditions. The post Why Elderly Americans Are Bearing the Brunt of the Government Shutdown’s Impact appeared first on MedCity…
Not All Military Payers Are the Same — And That Matters More Than Ever
Too often, providers handle all military claims the same way — sending them to the VA and hoping for the best. But there are multiple payer types, and they function very differently. The post Not All Military Payers Are the Same — And That Matters More Than Ever appeared first on MedCity News.
Sachin Jain–How do we do better?
What are the practices that we have normalized that future generations will criticize us for? Sachin Jain, CEO of SCAN Health Plan, is perhaps the leading truth teller in health care who also runs a real health care organization. I had a really fun but serious interview with Sachin about what health care people are…
Hospitals are Incompetent Monopolists!
By JEFF GOLDSMITH The health policy community is obsessed with hospital mergers. In a recent paper which I critiqued, the operating thesis was that hospital mergers are conspiracies in restraint of trade, enabling hospitals to extract rent from helpless local employers and patients. This logic leads directly to advocacy (lavishly funded by Arnold Ventures philanthropy) of hospital rate…
FDA Will Remove Warnings for HRT Products Used for Menopause
The FDA will remove black box warnings on hormone replacement therapies after evidence showed the risks were overstated. The post FDA Will Remove Warnings for HRT Products Used for Menopause appeared first on MedCity News.
How One CEO Thinks Ambient Scribes Can Differentiate Themselves
Startups in the ambient documentation space are moving beyond simple scribing to tools that can handle tasks like intake, coding and care coordination, according to Heidi Health CEO Tom Kelly. Standing out in this crowded market is a challenge, and companies’ success will hinge on creating products clinicians actually want to use, he added. The…
ISPOR Europe 2025!
Excited to have finished day 1 at ISPOR Europe in Glasgow, Scotland. Come check out my session on Tuesday with Tiago Beck at 11:30-12:00pm. EU Pharmaceutical Package: Where Are We and Where Are We Going? Speakers Tiago Beck, MSc, FTI Consulting, Brussels, Belgium; Jason Shafrin, PhD, FTI Consulting, Los Angeles, CA, United States As trilogue…
Health Care Costs Jump to the Fore as Candidates Jockey To Be California Governor
RIVERSIDE, Calif. — California’s gubernatorial election is a year away, and the field of primary candidates is still taking shape. But one persistent issue has already emerged as a leading concern: the cost of health care. At a forum Nov. 7 in the Inland Empire, four Democratic candidates vying to succeed Gov. Gavin Newsom vowed…
Eli Lilly Strikes Another Genetic Meds Deal, Gaining Global Rights to MeiraGTx Retinal Gene Therapy
Eli Lilly is paying $75 million up front for global rights to AAV-AIPL1, a gene therapy on track for U.S. and European regulatory submissions in the rare, inherited eye disorder Leber congenital amaurosis 4, or LCA4. The deal brings to Lilly another late-stage gene therapy for the eyes following the pharma giant’s October acquisition of…
